Company intelligence / Profile preview

SurgVision

Munich, Bavaria, Germany

Ownership: Private
Employees: ~10
Development stage: Other

Overview

SurgVision’s real-time fluorescence image-guided surgery technology has been demonstrated in six clinical trials (>160 patients, 2013–2019) and received FDA 510(k) clearance for the EXPLORER AIR® II system for ICG perfusion imaging and use with pafolacianine, enabling improved tumor visualization during surgery and interventional procedures

Therapeutic areas: OncologyGastroenterology
Modalities: DeviceImaging agentAntibody
Industry: Medical Imaging

Partnerships

Roche (clinical evaluation/collaboration for fluorescence-labeled bevacizumab imaging agent)Clinical academic partners (University Medical Center Groningen, Helmholtz Zentrum München)

Beyond the preview

Go deeper on SurgVision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SurgVision.

Explore the full profile